Epstein–Barr virus infection and plasma transforming growth factor-β1 levels in head and neck cancers

References

• Roberts CM, Foulcher E, Zaunder JJ, Bryant DH, Freund J, Cairns D, et al. Radiation pneumonitis: a possible lymphocyte-mediated hypersensitivity reaction. Ann Intern Med 1993; 118: 696–700
   PubMed Web of Science ®Google Scholar
• Anscher MS, Kong FM, Andrews K, Clough R, Marks LB, Bentel G, et al. Plasma transforming growth factor beta1 as a predictor of radiation pneumonitis. Int J Radiat Oncol Biol Phys 1998; 41: 1029–35
   PubMed Web of Science ®Google Scholar
• Li C, Wilson PB, Levine E, Barber J, Stewart AL, Kumar S. TGF-beta1 levels in pre-treatment plasma identify breast cancer patients at risk of developing post-radiotherapy fibrosis. Int J Cancer 1999; 84: 155–9
   PubMed Web of Science ®Google Scholar
• Feltl D, Zavadova E, Pala M, Hozak P. The dynamics of plasma transforming growth factor beta 1 (TGF-beta1) level during radiotherapy with or without simultaneous chemotherapy in advanced head and neck cancer. Oral Oncol 2005; 41: 208–13
   PubMedGoogle Scholar
• Feltl D, Zavadova E, Pala M, Hozak P. Posttreatment plasma transforming growth factor beta 1 (TGF-beta1) level predicts for late morbidity in patients with advanced head and neck cancer. Neoplasma 2005; 52: 393–7
   PubMed Web of Science ®Google Scholar
• Xu J, Menezes J, Prasad U, Ali A. Elevated serum levels of transforming growth factor β1 in Epstein-Barr virus-associated nasopharyngeal carcinoma patients. Int J Cancer 1999; 84: 396–9
   PubMed Web of Science ®Google Scholar
• Border WA, Ruoslahti E. Transforming growth factor-beta in disease: the dark side of tissue repair. J Clin Invest 1992; 90: 1–7
   PubMed Web of Science ®Google Scholar
• Cayrol C, Flemington EK. Identification of cellular target genes of the Epstein-Barr virus transactivator Zta: activation of transforming growth factor beta jgh3 (TGF-βigh3) and TGF-β1. J Virol 1995; 69: 4206–12
   PubMedGoogle Scholar
• Ahmad A, Menezes J. Binding of the Epstein-Barr virus to human platelets causes the release of transforming growth factor-beta. J Immunol 1997; 159: 3984–8
   PubMedGoogle Scholar
• Chen HW, Chang YC, Lai YL, Chen YJ, Huang MJ, Leu YS, et al. Change of plasma transforming growth factor-beta1 levels in nasopharyngeal carcinoma patients treated with concurrent chemo-radiotherapy. Jpn J Clin Oncol 2005; 35: 427–32
   PubMedGoogle Scholar
• Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205–16
   PubMed Web of Science ®Google Scholar
• Danielpour D. Improved sandwich enzyme-linked immunosorbent assays for transforming growth factor beta 1. J Immunol Methods 1993; 158: 17–25
   PubMed Web of Science ®Google Scholar
• Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics 1986; 42: 121–30
   PubMed Web of Science ®Google Scholar
• Grotendorst GR, Smale G, Pencev D. Production of transforming growth factor beta by human peripheral blood nomocytes and neutrophils. J Cell Physiol 1989; 140: 396–402
   PubMed Web of Science ®Google Scholar
• Liem LM, Fibbe WE, van Houwelingen HC, Goulmy E. Serum transforming growth factor-beta1 levels in bone marrow transplant recipients correlate with blood cell counts and chronic graft-versus-host disease. Transplantation 1999; 67: 59–65
   PubMed Web of Science ®Google Scholar
• Ewan KB, Henshall-Powell RL, Ravani SA, Pajares MJ, Arteaga C, Warters R, et al. Transforming growth factor-beta1 mediates cellular response to DNA damage in situ. Cancer Res 2002; 62: 5627–31
   PubMed Web of Science ®Google Scholar
• Anscher MS, Kong FM, Murase T, Jirtle RL. Short communication: normal tissue injury after cancer therapy is a local response exacerbated by an endocrine effect of TGF beta. Br J Radiol 1995; 68: 331–33
   PubMed Web of Science ®Google Scholar
• Stone, HB, Moulder, JE, Coleman, CN, Ang, KK, Anscher, MS, Barcellos-Hoff, MH, et al. Models for evaluating agents intended for the prophylaxis, mitigation and treatment of radiation injuries. Report of an NCI Workshop, December 3–4, 2003. Radiat Res 2004;162:711–28.
   PubMed Web of Science ®Google Scholar
• Anscher MS, Thrasher B, Rabbani Z, Teicher B, Vujaskovic Z. Antitransforming growth factor-β antibody 1D11 ameliorates normal tissue damage caused by high-dose radiation. Int J Radiat Oncol Biol Phys 2006; 65: 876–81
   PubMed Web of Science ®Google Scholar